anti-CD123 CAR T-cell therapy (TNK Therapeutics)

N/A

Report date: 2025/03/14 16:48:34

Base Information

Drug Nameanti-CD123 CAR T-cell therapy (TNK Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-3 receptor subunit alpha modulators

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTnk Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTnk Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A